YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage
- PMID: 3905967
YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage
Abstract
Two H-2 negative variants of the YAC-1 lymphoma were selected by mutagenization and sequential in vitro selections and compared with wild-type cells for changes in NK sensitivity and H-2 expression after interferon treatment or in vivo passage. The H-2 negative variants and the low H-2 expressor YAC-1 wild-type cells had similar NK sensitivity. However, IFN-beta or recombinant IFN-gamma pretreatments increased the H-2 expression of YAC-1 and protected them from NK lysis, whereas the H-2 variants, which remained H-2 negative, were not protected and often more sensitive to NK lysis. The H-2 variants were similarly susceptible as wild-type cells to three other cellular effects of interferon: protection from virus infection, modulation of Con A capping, and inhibition of cell proliferation. Thus, the only interferon-mediated effect that distinguished the H-2 negative variants from wild-type cells was the inability of the former to increase their H-2 expression and decrease their NK sensitivity. The wild-type YAC-1 line showed increased H-2 expression and decreased NK sensitivity after in vivo passage. In contrast, in vivo passaged H-2 variants showed no reexpression of H-2, and remained NK sensitive. The altered responses to interferon and in vivo passage were specific for loss or down-regulation of H-2, because Thy-1 loss (H-2 positive) YAC-1 variants behaved as the wild-type cells in all respects. This study supports the hypothesis that NK cells may function in vivo to eliminate host cells that fail to express H-2 after interferon stimulation during an immune response; such cells are a potential threat because they may escape recognition by T lymphocytes despite the expression of viral or tumor-associated antigens.
Similar articles
-
Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants.J Immunol. 1990 Jul 1;145(1):380-6. J Immunol. 1990. PMID: 2113557
-
H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.J Immunol. 1988 Mar 15;140(6):2096-102. J Immunol. 1988. PMID: 3126240
-
H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.J Immunol. 1988 Dec 15;141(12):4403-9. J Immunol. 1988. PMID: 3264312
-
Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.Crit Rev Immunol. 1993;13(1):1-34. Crit Rev Immunol. 1993. PMID: 8466640 Review.
-
Resistance to NK and metastatic potential of fibrosarcoma cells is associated with products encoded by the H-2D region.Semin Cancer Biol. 1991 Oct;2(5):329-36. Semin Cancer Biol. 1991. PMID: 1773048 Review.
Cited by
-
Expression and rearrangement of the alpha, beta, and gamma chain genes of the T cell receptor in cloned murine large granular lymphocyte lines. No correlation with the cytotoxic spectrum.J Exp Med. 1986 Aug 1;164(2):428-42. doi: 10.1084/jem.164.2.428. J Exp Med. 1986. PMID: 3723079 Free PMC article.
-
Hybrid resistance and the Ly-49 family of natural killer cell receptors.J Exp Med. 1995 Aug 1;182(2):273-7. doi: 10.1084/jem.182.2.273. J Exp Med. 1995. PMID: 7629493 Free PMC article. Review. No abstract available.
-
Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.J Exp Med. 1995 Oct 1;182(4):1005-18. doi: 10.1084/jem.182.4.1005. J Exp Med. 1995. PMID: 7561674 Free PMC article.
-
Antitumour actions of interferons: implications for cancer therapy.Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14. Nat Rev Cancer. 2016. PMID: 26911188 Review.
-
StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial.Ann Surg. 2011 Apr;253(4):672-83. doi: 10.1097/SLA.0b013e318210f3bd. Ann Surg. 2011. PMID: 21475006 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous